Guojun Yuan

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period”.

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(22)00277-7

N/A

4.0DataRank · unranked

188 citations

Wendy K. Chung, Hélène Dollfus, Robert Haws, Gabriel Ángel Martos‐Moreno, Christine Poitou +7 more

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

Contemporary Clinical Trials Communications(2021)10.1016/j.conctc.2021.100780

N/A

1.6DataRank · unranked

38 citations

Gregory Gordon, Joan C. Han, Jack A. Yanovski, Guojun Yuan, Murray Stewart +1 more